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Abstract
BACKGROUND: Preclinical data have indicated the anti–epidermal growth factor receptor (EGFR) agent cetuximab
(Erbitux) as a radiosensitizer in pancreatic cancer, but this has not been specifically addressed in a clinical study. We
report the results of an original study initiated in 2007, where cetuximab was tested with radiotherapy (RT) alone in locally
advanced pancreatic cancer in a phase II trial (PACER). METHODS: Patients (n = 21) received cetuximab loading dose
(400 mg/m2) and weekly dose (250 mg/m2) during RT (50.4 Gy in 28 fractions). Toxicity and disease response end point
data were prospectively assessed. A feasibility study of on-trial patient blood and skin sampling was incorporated.
RESULTS: Treatment was well tolerated, and toxicity was low; most patients (71%) experienced acute toxicities of
grade 2 or less. Six months posttreatment, stable local disease was achieved in 90% of evaluable patients, but
only 33% were free from metastatic progression. Median overall survival was 7.5 months, and actuarial survival was
33% at 1 year and 11% at 3 years, reflecting swift metastatic progression in some patients but good long-term con-
trol of localized disease in others. High-grade acneiform rash (P = .0027), posttreatment stable disease (P = .0059),
and pretreatment cancer antigen 19.9 (CA19.9) level (P = .0042) associated with extended survival. Patient skin and
blood samples yielded sufficient RNA and good quality protein, respectively. CONCLUSIONS: The results indicate that
cetuximab inhibits EGFR-mediated radioresistance to achieve excellent local control with minimal toxicity but does not
sufficiently control metastatic progression in all patients. Translational studies of patient tissue samples may yield
molecular information that may enable individual treatment response prediction.
Translational Oncology (2014) 7, 55–64
Address all correspondence to: Prof Patricia M. Price, Department of Surgery and Cancer, Imperial College London, B Block, The Hammersmith Hospital, Du Cane Road,
London, W12 0NN, United Kingdom. E-mail: p.price@imperial.ac.uk
1This study was funded by Cancer Research UK Feasibility (C153-A7727) and Programme (C153/A4331) grants, an Educational grant from Elekta Oncology Systems, and a
medical grant from Merck KGaA. G.A.W. was funded by a Cancer Research UK McElwain clinical research training fellowship. Additional facilitative support was provided by
National Institute for Health Research Cancer Research Network, Cancer Research UK (CRUK), the Christie NHS Foundation Trust, Merck KGaA, and the Experimental
Cancer Medicine Centre (ECMC). The authors have no conflicts of interest to declare.
Received 18 November 2013; Revised 7 February 2014; Accepted 10 February 2014
Copyright © 2014 Neoplasia Press, Inc. All rights reserved 1944-7124/14/$25.00
DOI 10.1593/tlo.13724
www.transonc.com
Trans la t iona l Onco logy Volume 7 Number 1 February 2014 pp. 55–64 55
Introduction
Unresectable, locally advanced pancreatic cancer (LAPC) is a devas-
tating disease with high morbidity. Median survival in randomized
trials remains low at only 7 to 14 months [1,2]. The main goals of
treatment are to balance palliation of symptoms and prolong life
while minimizing side effects. There is no consensus on the optimal
treatment regimen, and no specific treatment is recommended for
LAPC in the United Kingdom [3]. Current treatment approaches
may include best supportive care, radiotherapy (RT) only, single or
multiagent chemotherapy, chemotherapy followed by chemo-
radiotherapy (CRT), or immediate concurrent CRT. Only sufficient
inhibition of the local tumor in the absence of metastatic progression
(downstaging) such that resection is possible allows prolonged survival
in a minority of patients.
Although metastatic spread is a dominant concern, which has led
to systemic chemotherapy as the cornerstone of treatment, control of
local disease is important to prevent pain, gastrointestinal (GI) ob-
struction, ulceration, bleeding, cholangitis, and ultimately death due
to local disease advance alone [4]. Modern RT has important roles in
controlling local disease: to prevent disease symptoms, increase the
possibility of resection, and extend survival [5–9]. However, when
combined with chemotherapeutics to maximize disease control, the
effectiveness of treatment is limited by the radiation doses that can
be given safely, due to the risk of toxicity in surrounding radiosensitive
abdominal structures and the toxicity of the chemotherapy. Alternative
molecular targeted agents that enhance the RT response with minimal
toxicity and permit RT dose escalation are therefore of interest. Con-
formal RT alone has low toxicity and reasonable survival outcome com-
pared with other standard treatment approaches [10], providing scope
to test such agents independently.
Epidermal growth factor receptor (EGFR) overexpression and onco-
genic mutation of the downstream K-RAS signaling protein are com-
mon in pancreatic cancers and have been associated with increased
tumor aggressiveness and poor survival [11–17]. Furthermore, recent
experimental data have shown interdependence of EGFR signaling and
oncogenic K-RAS in pancreatic oncogenesis [18,19]. EGFR-mediated
radioresistance has been evidenced by EGFR activation and stimulation
of DNA repair by ionizing radiation [20,21], and the ability of anti-
EGFR agents to enhance radiation in pancreatic cancer has been
demonstrated in animal studies [22,23]. Cetuximab (Erbitux®; Merck
Serono Ltd, Feltham, UK) is an EGFR-specific chimeric IgG1 mono-
clonal antibody that inhibits EGFR-mediated signal transduction [24]
and radiation-induced DNA repair [25]. In animal models of pan-
creatic cancer, cetuximab has been shown to improve the treatment
efficacy of gemcitabine and radiation (gemcitabine + RT) [23,26,27].
An independent radiosensitizing effect of cetuximab has been shown in
a phase III head and neck cancer trial, where cetuximab + RT conferred
a survival advantage compared with RT alone [28]. However, although
phase I/II studies of cetuximab in combination with CRT approaches
in localized pancreatic cancer have shown some encouraging results
[29–33], the inclusion of systemic chemotherapeutics has confounded
interpretation of the contribution of cetuximab. As a result, it has
remained unclear whether cetuximab acts as an effective independent
radiosensitizer or if EGFR-mediated radioresistance plays a role in
treatment efficacy in patients with pancreatic cancer. To specifically
address these clinical science questions, a trial was initiated to eval-
uate cetuximab and conformal RT (cetuximab + RT) only for the
first time in patients with LAPC. The aim of the pancreatic cancer
cetuximab and radiotherapy (PACER) trial was to assess efficacy and
safety of the regimen with long-term follow-up. During the trial, a
translational substudy (PACER-TRANS) was instigated to investigate
the feasibility of on-trial patient blood and skin sampling for future
biomarker analysis.
Methods
Study
This study was a single-arm, multicenter, phase II, prospec-
tive national clinical trial (NCT00599833). It was supported by
Cancer Research UK (CRUK), Elekta Oncology, and Merck
KGA (Darmstadt, Germany), facilitated by the National Institute
for Health Research Cancer Research Network, approved by the
Greater Manchester Research Ethics Committee (06/Q1407/157),
and authorized by the Medicines and Healthcare products Regulatory
Agency (EudraCT 2006-001742-13). Hospital research and de-
velopment approval was obtained from the coordinating center
(The Christie NHS Foundation Trust) and other participating centers
(Leeds Teaching Hospitals NHS Trust and Betsi Cadwaladr Uni-
versity Health Board). The study was additionally approved by the
United Kingdom National Cancer Research Institute as part of the
upper GI studies group portfolio.
The trial was cautiously designed in 2006 with support from the
European Cancer Organisation Flims clinical trial design workshop,
using published evidence available at that time. A key concern was
the possibility of rapid disease progression, because of the lack of
cytotoxic chemotherapy agent and potential for the regimen to have
low activity. To minimize risk, the primary clinical end point selected
was progression-free survival (PFS) 6 months after the start of treat-
ment, and a Simon “Minimax” two-stage trial model was used to
minimize sample size and false rejection error [34]. This approach
allowed interim analysis to terminate the trial early if necessary.
The efficacy of the cetuximab + RT treatment was compared with
that of patients with LAPC who received other CRT regimens at
The Christie Hospital (Manchester, United Kingdom), using 6-month
PFS data determined by preceding audit. The specifications of the
trial were α = 0.05, power = 0.8, p0 = 0.25, and p1 = 0.45, where
p0 and p1 are the 6-month PFS rate under the null and alternative
hypotheses; i.e., if PFS < 25%, accept the null hypothesis that the regi-
men is less effective than other CRT treatments and terminate trial
early; if 25% < PFS < 45%, conclude that the regimen is no better
or worse than other current treatments; and if PFS > 45%, accept
the alternative hypothesis that the regimen has greater efficacy than
other CRT treatments. An independent data monitoring committee
advised initial recruitment of 21 patients to ensure at least 17 eligible
patient data sets for primary outcome assessment on interim analysis
(assuming dropout rate of 20%). If PFS and toxicity were considered
acceptable, recruitment could then continue up to 44 patients to ensure
at least 36 evaluable patients in total. RT dose escalation to 54 Gy in
30 fractions could also be considered. Secondary end points of the trial
were acute toxicity profile, tumor and overall disease posttreatment
Response Evaluation Criteria in Solid Tumors (RECIST) response,
freedom from local progression (FFLP), and overall survival (OS) up
to 3 years posttreatment. Amendments made to the trial after recruit-
ment was initiated included incorporating additional centers to enhance
recruitment and establishing a feasibility translational substudy (PACER-
TRANS) of patient blood and skin sampling for subsequent protein
and RNA analysis.
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Patients
All patients had biopsy-confirmed inoperable LAPC. The inability
to resect patients was determined by multidisciplinary team decision
(radiologist, surgeon, and treating oncologist) as due to tumor-related
factors before surgical approach or following invasive diagnostic
laparoscopy or attempted surgical approach. All patients gave written
informed consent and underwent an eligibility screening examina-
tion. This included full blood count, biochemistry profile, plasma
cancer antigen 19.9 (CA19.9), isotope renogram and baseline ab-
dominal computed tomography (CT) scan, and chest X-ray/thoracic
CT scans taken within 4 weeks of starting treatment. Inclusion crite-
ria included Karnofsky performance status (KPS) ≥ 60 plus adequate
hematological, hepatic, and renal functions, including hemoglobin
(Hb) ≥ 10 g/dl, white blood cells (WBC) ≥ 3.0 × 109/l, absolute
neutrophil count (ANC) ≥ 1.5 × 109/l, platelet count ≥ 100 × 109/l,
bilirubin ≤ 1.5 × upper limit of normal (ULN), alanine amino-
transferase (ALT) and aspartate aminotransferase (AST) ≤ 1.5 ×
ULN, alkaline phosphotase (ALP) ≤ 4 × ULN, creatinine ≤ 1.5 ×
ULN, and creatinine clearance > 50 ml/min. Adequate biliary drainage
with no evidence of active uncontrolled infection was required. Per-
mitted prior treatments were noncurative operation (e.g., palliative
bypass procedure or R2 resection with macroscopic, residual, localized
disease evident on CT scan) and/or biliary stent insertion. Exclusion
criteria included neuroendocrine histology or pancreatic lymphomas,
prior malignancy, chemotherapy, or any previous EGFR-targeted
therapy, or extensive disease unable to be covered in a radically treatable
RT volume.
Treatment
Patients were treated in specialist United Kingdom cancer centers
with modern RT units—The Christie Hospital, St James’ Institute
of Oncology (Leeds, United Kingdom), and the North Wales Cancer
Treatment Centre (Rhyl, United Kingdom). A quality assurance
program was implemented to ensure a high level of accuracy, and
consistency was achieved in RT planning and delivery between centers.
This included a clear RT protocol, dummy run, and central individual
case monitoring and review [35].
RT-planning CT scans were acquired with 50-mm slice thickness
in the treatment (supine) position after oral and IV contrast. The
clinical target volume was defined as the primary pancreatic tumor
plus CT-defined involved lymph nodes only. To ensure target cover-
age with motion, anterior-posterior and lateral margins of 17 mm
and a superior-inferior margin of 35 mm were applied [36] to pro-
duce the planning target volume (PTV). The maximum PTV allow-
able was 1000 ml, and the liver, spinal cord, and kidneys were
considered as organs at risk: maximum allowable radiation dose to
the spinal cord was 38 Gy, no more than 50% of the total liver vol-
ume was planned to receive more than 30 Gy (V 30 < 50%), and no
more than 30% and 50% of the contralateral and ipsilateral kidney,
respectively, were planned to receive more than 20 Gy (V 20 < 30%
and 50%). Treatment was planned isocentrically with the PTV
encompassed within the 95% isodose. A three- or four-field multi-
collimation technique was used without tissue density heterogeneity
correction. Patients received 50.4 Gy to the 100% isodose in 28 frac-
tions Monday to Friday for 5 1/2 weeks, starting in week 2. Daily
patient positioning was verified using tattoos and orthogonal laser
beams; treatment verification was performed daily using portal
imaging/cone beam CT for the first three fractions and weekly
thereafter, with a maximum variation tolerance of 5 mm.
During week 1, an initial loading dose (400 mg/m2) of cetuximab
was given intravenously (IV) over a 1 hour period, preceded by
IV chlorphenamine (10 mg). Patients were monitored closely for signs
of cetuximab sensitivity, and infusion was extended to 2 hours if
necessary. During weeks 2 to 7, cetuximab (250 mg/m2) was adminis-
tered once per week for 1 to 2 hours, again preceded by chlorphenamine
(10 mg) 2 to 4 hours before RT.
Patient Assessment
Baseline tumor assessment was either from diagnostic CT scans
(if taken within 4 weeks of starting treatment) or from RT-planning
CT scans. During treatment, clinical, hematological, and biochemical
assessments (including CA19.9 and magnesium levels) were under-
taken weekly. Acute toxicity was scored using the European Organisa-
tion for the Research and Treatment of Cancer (EORTC) Common
Toxicity Criteria for Adverse Events version 3 [37]. A diagnostic
contrast-enhanced CT scan was planned 26 weeks from the start of
treatment. Scans were brought forward for patients with clinical
signs of progression, and alternative treatment was offered according
to standard departmental protocol. For the purposes of the study,
RECIST criteria only were used to define primary tumor response
and disease progression [38]. Sites of primary disease progression
were determined by date of RECIST progression and defined by
radiologic description, documented clinical evidence, and (where
appropriate) postmortem report. Patients were followed up on a
3-monthly basis for the first year. Thereafter, follow-up was contin-
ued on a 6-monthly basis, for a minimum of 3 years or until death.
At each follow-up visit, patients underwent clinical, hematological,
and biochemical assessment, with CT scans undertaken when clin-
ically indicated.
Blood Samples and Skin Biopsies
Twenty milliliters of blood samples was taken before treatment,
weekly during treatment, and at the first follow-up, at the same time
as routine sampling for trial toxicity analyses. Blood plasma was
separated by centrifugation and stored at −20°C for subsequent
proteomic analysis.
Three-millimeter skin punch biopsies were taken following intra-
dermal local anesthetic. Basal fat was removed, and the skin tissue
was placed into sterile RNAlater (Life Technologies Corporation,
Carlsbad, CA). Mechanical disaggregation and homogenization were
carried out in TRIzol (Life Technologies Corporation). Phenol/
chloroform extraction and a PureLink centrifugation column (Life
Technologies Corporation) were used for RNA purification. Samples
were analyzed for quantity, integrity, and purity using an Agilent
2100 Bioanalyzer microfluidics platform (Agilent Technologies Inc,
Santa Clara, CA) and a NanoDrop light spectrophotometer (Thermo
Fisher Scientific Inc, Waltham, MA).
Statistics
Statistical analyses were performed using Stata version 9.2 (StataCorp,
College Station, Texas). FFLP, PFS, and OS data were analyzed using
Kaplan-Meier methodology. Survival times were calculated from the
first day of treatment to the date of objectively confirmed local disease
progression for FFLP, to the date of progression/death due to disease
progression for PFS, and to the date last seen or date of death for OS.
The log-rank test statistic was used to determine difference in survival
probability according to degree of acneiform rash and posttreatment
disease status. Cox proportional hazards model or the χ2 test was used
Translational Oncology Vol. 7, No. 1, 2014 PACER Phase II Trial and Translational Feasibility Study Rembielak et al. 57
as appropriate to determine the influence of pretreatment factors
(CA19.9, KPS, andHb levels) on PFS, OS, and posttreatment RECIST
disease status.
Results
Patients
Twenty-one eligible patients were recruited to the first stage of the
trial between October 2007 and March 2010. Slow accrual was
experienced due to high eligibility attrition (∼80%). The main reasons
were lack of confirmative biopsy; disease too advanced to be encom-
passed within RT field; patient’s informed refusal; poor KPS or in-
adequate hematological, hepatic, or renal function; or detection of
metastatic disease on staging/planning CT scan. As a result of slow
patient accrual, funding constraints, and dissolution of the Manchester
research department, patient recruitment was stopped at the end of the
first stage of the trial.
Patient and tumor characteristics are summarized in Table 1. Patient
toxicity and skin biopsy data are given in Tables 2 and 3, respectively.
Three patients underwent prior surgery: one a diagnostic laparoscopy,
one a failed trial dissection, and one a duodenal and biliary bypass.
All patients had T3/4 N0/1 disease (stage II/III) of at least 3 cm in
the longest dimension. No patients had “borderline resectable” disease,
showed symptoms of neuroendocrine disease, could/would not undergo
surgery, nor were lost to follow-up. Comprehensive individual pa-
tient data, including toxicity and outcome information, are given in
Table 4.
RT Plan Characteristics
Twenty of 21 (95%) patients received IV and oral contrast for their
RT-planning CT scan (contrast omitted in one patient due to tempo-
rarily raised creatinine). Median PTV volume was 392.4 cm3 (range =
212.2-712.3). Median liver volume receiving ≥30 Gy was 12.0%
(0%-50%), and median maximal dose to the spinal cord was 20.4 Gy
(range = 8.7-36.9 Gy). Median volumes of the left and right
kidneys receiving ≥20 Gy were 1.4% (range = 0%-28.2%) and
2.0% (range = 0%-28%), respectively.
Treatment Compliance and Toxicity
All 21 patients tolerated cetuximab infusion well. Seventeen patients
(81%) received the full planned course of cetuximab, and 20 (95%)
received the full planned RT dose. Single cetuximab doses were omitted
for three patients because of acute pericarditis, grade 3 acneiform rash,
and liver abscess, respectively, all of which resolved before the next due
dose. Doses were also omitted in another patient from week 4 due to
study withdrawal. This followed clinical deterioration consistent with
local and metastatic disease progression. The patient was changed to
a palliative RT course such that they received a total dose of 28.8 Gy
in 16 fractions.
Acute toxicity was low (≤grade 2) in most (71%) patients. The
most common all-grade acute toxicities were acneiform rash
(95%), fatigue (86%), nausea (67%), diarrhea and anorexia (both
62%), pruritus, desquamation, and dry skin (all 57%). Acute toxici-
ties ≥ Grade 2 are summarized in Table 2. Eleven incidences of
grade 3 and one grade 4 serious adverse events (SAEs) were reported
in six patients during the 7 weeks of active treatment, although
four SAEs occurring in two patients were considered unlikely to
be related to treatment (pericarditis and associated fatigue in one
patient; liver abscess and associated abdominal pain in another).
Two grade 3 SAEs occurred after treatment was completed: one
was hypomagnesemia and hypocalcemia at 8 weeks, which was
considered definitely related to cetuximab treatment (known side
effect); the other was GI bleeding at 14 weeks, which was possibly
related to RT treatment.
Table 1. Patient and Tumor Characteristics.
Patient and Tumor Characteristics n (%)
Gender
Male 13 (62%)
Female 8 (38%)
KPS
70-80 5 (24%)
90-100 16 (76%)
Tumor location
Head 17 (81%)
Body 3 (14%)
Head and body 1 (5%)
Histology
Adenocarcinoma 19 (90%)
Not specified 2 (10%)
Prior treatment
Biliary stent 15 (72%)
Other surgery 3 (14%)
CA19.9
Below ULN: <30 U/ml 6 (29%)
Raised: >30 U/ml (ULN) 15 (71%)
Raised: Median (range; U/ml) 511 (136-26328)
Hb
Normal 15 (71%)
Anemia (Hb < 12/14 g/dl) 6 (29%)
Age
Median (range) 65 (47-80) yr
Weight
Median (range) 65.5 (46.3-100.2) kg
Table 2. Incidence of Acute Toxicity ≥ Grade 2.
Toxicity Number of Patients (n = 21)
Grade 2 Grade 3 Grade 4
Skin
Acneiform rash 11 1 -
Pruritis/itching 1 - -
Rash/desquamation 3 - -
Dry skin 3 - -
GI
Anorexia 6 1 -
Abdominal bloating 4 - -
Diarrhea - 1 -
Nausea 3 - -
Vomiting - 1 -
Enteritis 1 - -
Gastritis 1 - -
Oral mucositis 2 - -
Bleeding - 1 -
Other
Fatigue 6 2* -
Pain 5 2* -
Anemia 2
Hyperbilirubinemia 1 - -
Thrombocytopenia 1 - -
Pericarditis - 1* -
Hyperglycemia - 1 -
Infection - - 1*
*Pericarditis with associated fatigue in one patient and liver abscess with associated abdominal pain
in another patient were reported as SAEs but judged unlikely or not related to treatment.
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Patient Follow-Up and Outcome Measures
Following treatment (and subsequent photodynamic therapy as
part of a phase 1 trial), one patient had a Whipple procedure
with complete excision of residual pancreatic adenocarcinoma,
plus adjuvant chemotherapy. Four patients received palliative
chemotherapy on disease progression, and one received additional
chemotherapy when entering another trial (TeloVac). One patient,
who developed early bony metastases, received palliative spinal RT.
Posttreatment CT scans were brought forward for seven patients. As
a result, the median time from start of treatment to posttreatment
scan was 23.9 weeks. Three recruited patients were ineligible for
progression/survival outcome on “per protocol” analysis. One was
excluded because they failed to complete treatment (withdrawn),
and two were retrospectively radiologically determined to have had
metastatic spread before treatment, as lung lesions were detected on
posttreatment chest CT, which were apparent but indeterminable
on pretreatment abdominal CT/chest X-ray.
Of the remaining 18 assessable patients, 14 patients were eva-
luable for posttreatment primary target lesion response (Figure 1).
Nonevaluability was because the primary target lesion was ill de-
fined on CT, inhibiting definitive measurement (two patients), or
the planned posttreatment CT scan was not performed due to pa-
tient condition/disease progression (two patients). Local control
was high. Only one patient (P18) showed a tumor size increase
consistent with RECIST local progression (>20%) and concurrent
development of metastatic disease at 3.7 months. In the majority
of remaining patients, the primary tumor either reduced in size
(range = 2-38 mm) or stayed the same. Two patients (P19 and
P21) showed tumor size decreases consistent with RECIST partial
response (>30%).
Local control remained high posttreatment with 90% FFLP at
6 months and 1 year (Figure 2A). However, crude posttreatment
(median = 23.9 weeks) overall RECIST response rates showed 12
of 17 (71%) patients with progressive disease (PD), and only 5 of
17 (29%) with stable disease (SD). The predominant initial site of
progression was intraabdominal (liver, duodenum, stomach, and
ascites), but a more widespread pattern of first progression was noted
in patients with posttreatment PD: three had subcutaneous nodules in
the umbilical area, and another had bone metastasis. Median PFS was
5.1 [95% confidence interval (CI) = 4.6-6.2] months (Figure 2B).
Actuarial PFS was 33.3% (95% CI = 13.7-54.5) at 6 months and
22.2% (95% CI = 6.9-42.9) at 1 year. There was a trend for patients
who developed grade 2 or more acneiform rash to have better PFS
(Figure 2C ; P = .0651).
Median OS was 7.5 (95% CI = 6.4-12.7) months (Figure 3A).
Actuarial OS was 33% at 1 year and 11% at 2 and 3 years (two pa-
tients were alive and progression free at 3 years). Log-rank analysis
showed that the degree of acneiform rash (Figure 3B; P = .0027) and
Figure 1. Waterfall plot of percentage of change in primary tumor
longest dimension in 14 evaluable patients with LAPC following
cetuximab + RT treatment (median = 23.9 weeks posttreatment).
Tumor size was objectively assessed on CT. Individual patient data
are given from worst to best response.
Figure 2. Kaplan-Meier disease progression analysis in 17 patients
with LAPC following treatment with cetuximab + RT. (A) FFLP.
(B) PFS. Median (95% CI) = 5.1 (4.6-6.2) months. (C) PFS and acnei-
form rash (log-rank P = .651).
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posttreatment RECIST SD status (Figure 3C ; P = .0059) were prog-
nostic for OS. Cox proportional hazards model showed that pretreat-
ment CA19.9 level > 1000 U/ml was prognostic for reduced OS (P =
.042). There were no statistical associations between pretreatment
anemia and KPS with PFS, OS, or posttreatment SD.
Biopsy Substudy
Of the 10 patients approached, 5 consented to donate blood sam-
ples, and 2 consented to skin biopsies. Blood samples from three
patients were processed and analyzed in a proteomics-based bio-
marker study [39]. RNA sample parameters from skin biopsies are
shown in Table 3. Samples obtained varied in yield, purity, and
integrity of obtained RNA.
Discussion
There is no consensus on the best treatment for LAPC, and patient
outcomes remain poor. Improved biologic understanding of the disease
and investigation of novel mechanism-based therapeutics are required
to facilitate the development of more effective treatments with reduced
toxicity. PACER is the first study to investigate cetuximab+RT alone in
pancreatic cancer and indicates the efficacy of cetuximab as an EGFR-
targeted radiosensitizer, consistent with preclinical studies. The results
are important and relevant to current advances in pancreatic cancer as
it provides benchmark data, in the absence of chemotherapy, for com-
paring and evaluating other RT + cetuximab–containing regimens.
PACER was also the first trial of patient normal tissue sampling feasi-
bility during an experimental treatment for pancreatic cancer. The key
limitation of the study was the inability to continue to recruit in the
second stage, which impacts on the study size and power.
Cetuximab was well tolerated; the prophylactic use of IV chlor-
phenamine is likely to have prevented the infusion reactions and other
severe adverse events reported by others [29,40]. Only one (4.8%)
patient experienced one short-term incidence of grade 3 acneiform
rash. Toxicity was considerably lower compared with other CRT regi-
mens, and no patient experienced any hematological toxicity > grade 2
[7,8,10,33,41]. Despite relatively large PTVs (median = 392.4 cm3),
only two patients (9.5%) suffered with any GI toxicity > grade 2. This
may have been aided by limited-field RT, but unlike a previous study
that also omitted uninvolved nodes, we found no statistical relationship
between large PTV (>260 cm3) and GI toxicity [8].
Excellent local control was achieved. Large decreases in tumor size
were seen in some patients, and one patient (5.5%) subsequently
underwent Whipple resection. Although rarely reported for chemo-
therapy regimens, local control was higher than the ∼70% achieved
in a trial arm of gemcitabine only [7], and no patients showed local
Figure 3. Kaplan-Meier disease survival analysis in 17 patients with
LAPC following treatment with cetuximab + RT. (A) OS. Median
(95% CI) = 7.5 (6.4-12.7) months. (B) OS and acneiform rash (log-
rank P = .0027). (C) OS and posttreatment SD (log-rank P = .0059).
Table 3. RNA Yield and Purity from Skin Biopsies.
Sample Tissue Weight (mg) RNA Yield (ng/μl) Absorption (260/280) Absorption (260/230) RIN
P4-IN* posttreatment 10 104.5 1.55 0.21 N/A
P4-OUT* posttreatment 11 46.8 2.07 2.15 8.4
P6-IN pretreatment 4.4 37.8 1.83 1.03 6.9
P6-OUT pretreatment 2.3 50.9 1.93 1.3 3.2
P6-IN posttreatment 22 103.8 1.94 1.34 8.1
P6-OUT posttreatment 40 155.7 1.97 1.53 7.9
260/280, ratio of sample absorption at wavelength 260 nm and at 280 nm; 260/230, ratio of sample absorption at wavelength 260 nm and at 230 nm; RIN, RNA integrity number.
*P4 and P6 donated skin samples from inside (IN) and outside (OUT) the RT field pretreatment and/or posttreatment.
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disease progression only, unlike the 30% reported from autopsies of
patients with pancreatic cancer [4]. Compared with other CRT regi-
mens, a similarly high crude rate of stable local disease posttreatment
(95%) has been reported in a trial of cetuximab + gemcitabine +
intensity-modulated RT [33]. The 90% FFLP at 1 year was better
than that reported by other contemporary CRT trials that used
similar size measures of local control, including 64% reported in a
trial of full-dose gemcitabine + RT [8] and 77% reported in a trial
of induction cetuximab + gemcitibine + oxaliplatin, followed by
cetuximab + capecitabine + RT [29]. The RT methodology, using
limited field, IV contrast to minimize tumor CT underestimation, and
margins incorporating on-treatment motion [36,42,43], may have aided
the high rate of local control.
The PFS rate of 33% at 6 months meant that the trial could have
proceeded to the second stage and indicated that the regimen was
comparable to standard CRT regimens. In light of the low toxicity
obtained, the RT dose may have been increased in the second stage as
intended in the trial protocol. Although the actuarial PFS at 12 months
(22.2%) was similar or better than recent trials of gemcitabine + RT
[7,41], the median PFS at 6 months (33%) was low compared with
other recent CRT trials [5,7,8,41,43]. Notably, five patients (28%)
fared particularly badly and progressed before 20 weeks. Early meta-
static progression is not uncommon in LAPC, and the presence of
metastases occult to CT detection is believed to be responsible; e.g.,
15% to 33% of patients are reported to develop metastatic disease dur-
ing induction chemotherapy [44]; and in a recent randomized trial of
gemcitabine + intensity-modulated RT, ∼20% of patients overall pro-
gressed before 20 weeks [7]. The rapid progression seen in some
patients and the lower median PFS suggest the presence of occult
metastases and aggressive disease growth and dissemination, which
was not effectively controlled by the predominately localized effects
of cetuximab + RT.
The median OS was at the lower end of the range (7-14 months)
reported from other recent CRT- and chemotherapy-trialled regi-
mens [1,2]. This is most likely due to the swift metastatic progression
seen in some patients. Nevertheless, OS was respectable for late-stage
unresectable patients, and analysis was informative. Both OS and
response rate were greater than those reported in previous trial arms
of RT treatment alone, despite having more patients with higher
stage disease in this study [10,45]. Survival was also considerably better
than that reported for best supportive care only in patients with LAPC
[9]. Although 1-year survival at 33% was less than the 40% to 70%
reported for other CRT treatments associated with higher toxicities
[5–9,46], it compares well with ∼18% 1-year survival reported by
CRUK for patients with all-stage (and all-treatment) pancreatic cancer
[47]. Most importantly, 11% of patients survived more than 3 years,
which was considerably more than that reported for other higher
toxicity CRT regimens, including 5-fluorouracil + RT, gemcitabine +
RT, and capecitabine + RT [5,7–9,41,46]. The association of post-
treatment SD with survival lends support to other studies showing
the importance of local control for patient outcome [5–8]. The associ-
ation of cetuximab-induced acneiform rash with survival has been
shown before [29] and indicates that cetuximab + RT efficacy was
linked to patient cetuximab sensitivity. The association between high
pretreatment CA19.9 level and CRT outcome confirms other findings
[48,49] and suggests that increased tumor load or aggressive phenotype
reduced cetuximab + RT efficacy.
Taken together, the results indicate cetuximab as an effective
radiosensitizer in pancreatic cancer, consistent with preclinical data
[22,23,25–27]. The treatment enabled very good control of local
disease without substantially increasing toxicity, which importantly
resulted in prolonged survival in some patients. The radiosensitizing
efficacy of cetuximab may have particular relevance for improving
local control and, in particular, increasing resectability rates in LAPC
[50,51]. However, the ability of cetuximab + RT to inhibit meta-
static growth and dissemination was insufficient in most patients
and appeared to be related to individualized cetuximab sensitivity
and tumor propensity for metastasis. There are three lines of support
in accordance with these findings: first, patient sensitivity and skin
reactions to cetuximab are known to vary; second, translational studies
have indicated metastatic pancreatic cancer development as either pro-
gressive stages of a linear model of metastases or distinct morphologic/
genetic cancer subtypes [52]; and third, testing cetuximab in combina-
tion with RT in locally advanced disease has shown encouraging results
[29,30,32,33], whereas cetuximab tested with chemotherapy agents in
advanced pancreatic cancer has not [53–55]. Susceptibility to EGFR-
targeted therapy in pancreatic cancer has been suggested to be mediated
by tumor K-RASmutational status [13,15,17], as assumed in colorectal
cancer, but recent evidence has shown interdependence rather than
mutually exclusive action of oncogenic K-RAS and EGFR signaling
to drive pancreatic oncogenesis [18,19]. A radiosensitizing mechanism
independent of K-RAS status is therefore possible [27,56,57]. Alter-
natively, both metastatic potential and cetuximab sensitivity could be
influenced by cellular or nuclear levels/activity of EGFR [11,12] or
avain erythroblastic leukaemia viral oncogene homolog 2 (ERBB2)
signaling activation [58].
It is likely that improved cohort PFS and OS would be gained
with the use of induction chemotherapy before cetuximab + RT
treatment—resulting from selecting out patients destined to progress
early with aggressive occult metastatic disease [44] or by incorporat-
ing concurrent cytotoxic chemotherapy agents to the cetuximab +
RT regimen—to improve control of metastatic disease but at the
expense of increasing toxicity [29,32,33]. For CRT approaches that
include cetuximab, the RTmethodology, inclusion of chlorphenamine/
non-steroidal anti-inflammatory drugs (NSAIDs)/steroids, and choice
of chemotherapy agent appear to be important to reduce adverse events
[29,32,33]. It is additionally important to recognize that some patients
responded well to cetuximab + RT alone. However, there is currently
no pretreatment method to identify these patients. Improved staging
could enhance patient selection for localized treatment, e.g., with
high-sensitivity fluorodeoxyglucose-positron emission tomography
(FDG-PET), laparoscopy, or circulating tumor cell assay to detect CT
occult disease. Our results also suggest that high pretreatment CA19.9
levels as an indicator of aggressive disease and initial testing of patient
cetuximab sensitivity by rash induction may help to select patients
who would be most responsive to cetuximab radiosensitization. Predic-
tion of individual patient response would have ultimate benefit for the
selection of patients for the most appropriate therapeutic approach,
highlighting the need to return to translational studies to elucidate
mechanisms and markers of cetuximab + RT efficacy.
To date, biologic investigation of pancreatic cancer and thera-
peutic response has been largely confined to pathologic material or
in vitro models. Normal skin samples may be useful for assessment
of EGFR expression or predicting cetuximab sensitivity. However,
we found that patients were generally unwilling to consent to skin
sampling, plus the processing was difficult and resulted in variable
RNA quality. Blood samples were easily obtainable during routine
treatment monitoring and resulted in valuable longitudinal samples
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suitable for ongoing proteomics studies. We would therefore rec-
ommend blood sampling to be prioritized, with integration of con-
sent into trials. In an initial blood proteomics study of three patients
studied here, differentially expressed proteins were observed between
patients at baseline [39], indicating patient variability that may be
useful for determining molecular treatment sensitivity. In addition to
EGFR, K-RAS and ERBB2, other molecules associated with cetuximab
resistance, metastatic development, or aggressive phenotype include
SMAD family member 4/deleted in pancreatic carcinoma locus 4
(SMAD4/DPC4) [4,29] and thusmay have relevance in the elucidation
of cetuximab + RT mechanism of action or prediction of individual
treatment response.
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